spacer
home > ict > winter 2020 > we can do better: key considerations for paediatric trial success
PUBLICATIONS
International Clinical Trials

We Can Do Better: Key Considerations for Paediatric Trial Success




Parents naturally become anxious when their children are unwell, and that is generally increased when the child needs hospital treatment or when certain procedures, surgery, or conditions are mentioned. In such settings, parents may not be immediately receptive to enquiries about their child participating in clinical research. However, once the discussion with the investigator is underway, a range of additional obstacles often come to the surface, many of which we have the ability to minimise.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Mark Sorrentino, MD and MS, Vice President of the Center for Pediatric Clinical Development, at PRA Health Sciences has more than 20 years of experience in the pharma and biotechnology industries and currently leads PRA’s global paediatric centre of excellence. Mark holds an appointment as an Assistant Clinical Professor at the George Washington University School of Medicine, US. Prior to joining PRA, he spent five years as the Global Chair and Founder of the paediatric practice area at a leading CRO, overseeing all aspects of strategy and paediatric clinical development, and the Global Therapeutic Head of Critical Care.
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioNet and Sartorius’ company BIA Separations collaborate on production process development of mRNA vaccines

Ajdovšcina, Slovenia & Bangkok, Thailand, 02 November 2021: BioNet, a leading biotech company manufacturing genetically engineered vaccines, and BIA Separations, now part of Sartorius, a leading biochromatography development and manufacturing company, today announced the successful development of an optimized mRNA manufacturing process.
More info >>

White Papers

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

DiagnostikNet-BB

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement